|
|
Article: Aegera Initiates Phase 1 Oncology Clinical Trial of XIAP Antisense Designed to Stimulate Apoptotic Cell Death in Cancer Cells.
- Article from:
- PR Newswire
- Article date:
- March 29, 2004
CopyrightCOPYRIGHT 2004 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Aegera Therapeutics Inc. is pleased to announce the initiation of Phase 1 clinical trials for AEG35156/GEM(R)640, an antisense inhibitor of X-linked Inhibitor of Apoptosis Protein (XIAP), in collaboration with Cancer Research UK. AEG35156 is a 2nd generation antisense oligonucleotide, which is designed to reduce high levels of XIAP protein in cancer cells and thereby enable apoptotic cell death. The first patient was enrolled at the Christie Hospital in Manchester by Principal Investigator, Dr. Malcolm Ranson, MBChB, PhD, Director of the Derek Crowther Trials Unit. The trial is also being conducted at a second site, Cancer Research UK Oncology Unit within the University ...